FDA puts on hold two drug trials of Rapt Therapeutics in 'major setback'

The patient had a drug allergy to Dupixent, Regeneron and Sanofi's drug for the conditions, and had also undergone thyroid hormone replacement therapy for an autoimmune condition called Hashimoto's disease, CEO Brian Wong said in a conference call.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/c9oE6HX
via